You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Testing of biological medicines
Applicable to biological medicines, excluding vaccines, anti-venoms and toxins
Our testing program uses a risk-based strategy to prioritise testing. This allows us to focus on high risk products, while testing lower risk products less frequently, or with less labour-intensive methods. Products that have not yet established a track record of quality and safety, such as new products, and products associated with adverse drug reactions or manufacturing failures are considered high risk products.